EU Court upholds 52.5m euro fine against AstraZeneca Group

Global biopharmaceutical group AstraZeneca (AZ) has lost an appeal over a 52.5m euro fine relating to the way that its subsidiaries AstraZeneca AB and AstraZeneca Plc marketed an ulcer-treating drug.

Global biopharmaceutical group AstraZeneca (AZ) has lost an appeal over a 52.5m euro fine relating to the way that its subsidiaries AstraZeneca AB and AstraZeneca Plc marketed an ulcer-treating drug.

The case, which dates back to 2005 and has been subject to two appeals, surrounds the way that the group made representations to the patent offices of certain Members states.

The Court of Justice of the European Union stated that the group had abused its dominant position by preventing the marketing of generic products replicating Losec, its ulcer-treating drug.

The Court announced on Thursday that it had rejected the arguments advanced by the two companies owned by AstraZeneca. It concluded that the General Court was fully entitled to hold that AstraZeneca's conduct was in breach of competition on the merits and therefore counted as an abuse of a dominant position.

A spokesperson at AstraZeneca commented to ShareCast: "AZ is disappointed with the Court of Justice's decision that AZ's appeal should be dismissed. AZ takes compliance with all laws seriously and has a fundamental commitment to doing business in an ethical and proper manner."

AstraZeneca's share price was unchanged at 12:02 on Thursday.

MF

Recommended

The top funds to invest in
Funds

The top funds to invest in

Investors continue to favour passive funds in April though figures reveal an actively managed money market fund also caught their eye. We look at wher…
3 May 2023
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
20 Apr 2023
Best junior stocks and shares ISA platforms
Isas

Best junior stocks and shares ISA platforms

A junior stocks and shares ISA is a great way to save for your child tax-efficiently. But it can be confusing deciding which investment platform to ch…
28 Mar 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023

Most Popular

June’s NS&I Premium Bond prize draw - are you this month’s millionaire?
Savings

June’s NS&I Premium Bond prize draw - are you this month’s millionaire?

Two fortunate NS&I Premium Bond winners are now millionaires. Find out here if you’re one of them.
1 Jun 2023
The best one-year fixed savings accounts - June 2023
Savings

The best one-year fixed savings accounts - June 2023

You can now earn 5% on 1 year fixed savings accounts - the best rate seen in 14 years. We have all the latest rates available now.
2 Jun 2023
The top healthcare funds to buy
Investments

The top healthcare funds to buy

Increasingly rapid progress in drugs and healthcare technology makes these trusts top tips, says Max King.
1 Jun 2023